Figure 3.

α/β-Peptide 6 demonstrates long-lasting improvement of in vivo glucose tolerance. (A) Plasma glucose values during a glucose tolerance test (GTT) for mice treated with GLP-1(7–37)-NH₂ (1 mg/kg), exendin-4 (Ex-4, 1 mg/kg), varying doses (0.01 to 1 mg/kg) of α/β-peptide 6 or vehicle. Upward arrow indicates timing of the peptide treatments delivered via IP injection. Results show mean (±SEM) of 4 separate mice per condition. (B) Average area under the curve (AUC) values for the GTT data shown in part A. (C) Plasma glucose values at 30 min following a second GTT that was conducted 5 h following that shown in A. *, P < 0.05 vs vehicle.